↓ Skip to main content

Gene Therapy of Cancer

Overview of attention for book
Cover of 'Gene Therapy of Cancer'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer
  3. Altmetric Badge
    Chapter 2 Designing Adenoviral Vectors for Tumor-Specific Targeting
  4. Altmetric Badge
    Chapter 3 Analysis of HSV Oncolytic Virotherapy in Organotypic Cultures
  5. Altmetric Badge
    Chapter 4 Use of Minicircle Plasmids for Gene Therapy
  6. Altmetric Badge
    Chapter 5 Transposable Elements as Plasmid-Based Vectors for Long-Term Gene Transfer into Tumors
  7. Altmetric Badge
    Chapter 6 Designing Plasmid Vectors
  8. Altmetric Badge
    Chapter 7 Development of Bacterial Vectors for Tumor-Targeted Gene Therapy
  9. Altmetric Badge
    Chapter 8 Electroporative Gene Transfer
  10. Altmetric Badge
    Chapter 9 Gene Gun Delivery Systems for Cancer Vaccine Approaches
  11. Altmetric Badge
    Chapter 10 Ultrasound-Mediated Gene Transfection
  12. Altmetric Badge
    Chapter 11 Nonviral Jet-Injection Technology for Intratumoral In Vivo Gene Transfer of Naked DNA
  13. Altmetric Badge
    Chapter 12 Methods for Constructing and Evaluating Antitumor DNA Vaccines
  14. Altmetric Badge
    Chapter 13 Immunity of Lentiviral Vector-Modified Dendritic Cells
  15. Altmetric Badge
    Chapter 14 Saporin Suicide Gene Therapy
  16. Altmetric Badge
    Chapter 15 Using In Vivo Biopanning for the Development of Radiation-Guided Drug Delivery Systems
  17. Altmetric Badge
    Chapter 16 Chemosensitization of Tumor Cells: Inactivation of Nuclear Factor-Kappa B Associated with Chemosensitivity in Melanoma Cells After Combination Treatment with E2F-1 and Doxorubicin
  18. Altmetric Badge
    Chapter 17 Induction of Tumor Cell Apoptosis by TRAIL Gene Therapy
  19. Altmetric Badge
    Chapter 18 Silencing Epidermal Growth Factor Receptor by RNA Interference in Glioma
  20. Altmetric Badge
    Chapter 19 Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells.
  21. Altmetric Badge
    Chapter 20 Use of RNA Aptamers for the Modulation of Cancer Cell Signaling
  22. Altmetric Badge
    Chapter 21 G-Rich Oligonucleotides for Cancer Treatment
  23. Altmetric Badge
    Chapter 22 Regulatory Aspects for Translating Gene Therapy Research into the Clinic
  24. Altmetric Badge
    Chapter 23 Ethics of Cancer Gene Transfer Clinical Research
  25. Altmetric Badge
    Chapter 24 Virus Production for Clinical Gene Therapy
  26. Altmetric Badge
    Chapter 25 Production of Plasmid DNA as Pharmaceutical
  27. Altmetric Badge
    Chapter 26 Gene Immunotherapy for Non-Small Cell Lung Cancer
  28. Altmetric Badge
    Chapter 27 Gene Therapy for Antitumor Vaccination
  29. Altmetric Badge
    Chapter 28 HSV-tk/IL-2 Gene Therapy for Glioblastoma Multiforme
  30. Altmetric Badge
    Chapter 29 Construction and Characterization of an Oncolytic HSV Vector Containing a Fusogenic Glycoprotein and Prodrug Activation for Enhanced Local Tumor Control
  31. Altmetric Badge
    Chapter 30 Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.
  32. Altmetric Badge
    Chapter 31 Oncolytic Viral Therapy Using Reovirus
  33. Altmetric Badge
    Chapter 32 Design and Testing of Novel Oncolytic Vaccinia Strains
  34. Altmetric Badge
    Chapter 33 Tumor-Targeted Salmonella typhimurium Overexpressing Cytosine Deaminase: A Novel, Tumor-Selective Therapy
  35. Altmetric Badge
    Chapter 34 Chemoprotection by Transfer of Resistance Genes
  36. Altmetric Badge
    Chapter 35 Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxorubicin, and Cisplatin Chemotherapy in Patients with Advanced Sarcomas
Attention for Chapter 30: Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
3 X users
patent
2 patents

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
77 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.
Chapter number 30
Book title
Gene Therapy of Cancer
Published in
Methods in molecular biology, January 2009
DOI 10.1007/978-1-59745-561-9_30
Pubmed ID
Book ISBNs
978-1-934115-85-5, 978-1-59745-561-9
Authors

Schirrmacher V, Fournier P, Volker Schirrmacher, Philippe Fournier, Schirrmacher, Volker, Fournier, Philippe

Abstract

This review deals with the avian paramyxovirus Newcastle disease virus (NDV) and describes properties that explain its oncolytic activity, its tumor-selective replication behavior, and its immune-stimulatory capacity with human cells. The strong interferon response of normal cells upon contact with NDV appears to be the basis for the good tolerability of the virus in cancer patients and for its immune stimulatory properties, whereas the weak interferon response of tumor cells explains the tumor selectivity of replication and oncolysis. Various concepts for the use of this virus for cancer treatment are pointed out and results from clinical studies are summarized. Reverse genetics technology has made it possible recently to clone the genome and to introduce new foreign genes thus generating new recombinant viruses. These can, in the future, be used to transfer new therapeutic genes into tumors and also to immunize against new emerging pathogens. The modular nature of gene transcription, the undetectable rate of recombination, and the lack of a DNA phase in the replication cycle make NDV a suitable candidate for the rational design of a safe and stable vaccine and gene therapy vector.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 2 3%
Unknown 75 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 17%
Student > Master 12 16%
Researcher 10 13%
Student > Bachelor 7 9%
Student > Doctoral Student 4 5%
Other 10 13%
Unknown 21 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 22%
Agricultural and Biological Sciences 17 22%
Immunology and Microbiology 8 10%
Medicine and Dentistry 3 4%
Psychology 3 4%
Other 4 5%
Unknown 25 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2019.
All research outputs
#3,249,865
of 22,655,397 outputs
Outputs from Methods in molecular biology
#794
of 13,011 outputs
Outputs of similar age
#16,363
of 168,686 outputs
Outputs of similar age from Methods in molecular biology
#20
of 157 outputs
Altmetric has tracked 22,655,397 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,011 research outputs from this source. They receive a mean Attention Score of 3.3. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,686 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 157 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.